Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report which predicts that there will be at least one anti-obesity blockbuster by 2012 and multi-billion revenues for the segment by early next decade.
“Anti-Obesity Treatments 2007-2012 - A Blockbuster Target Market” finds that by 2010, almost 50% of children in North America and 38 % of those in the European Union will be overweight. Obesity is also the most common nutritional disorder in Western, industrialised countries. These statistics lead analysts to predict that the anti-obesity drug treatment market offers unique opportunities for pharmaceutical companies who are looking to target successful markets.
The report critically examines the commercial prospects for anti-obesity prescription drugs in the global healthcare market, especially in the U.S and Europe where obesity is being described as an epidemic and a "public health time-bomb". It finds that there are several factors aiding the potential success of anti-obesity drugs, notably the increase in Government funding to tackle the problem, and also growing acceptance of the drug-class from stakeholders.
Analysts however say that it will not be all smooth sailing for pharmaceutical companies as there are many hurdles that need to be overcome before drugs are launched successfully. For instance, there is a growing demand from healthcare authorities and practitioners that anti-obesity drugs are efficacious, safe and cost-effective. A case in point is the recent rejection by the Food and Drug Administration advisory panel of Sanofi-Aventis' obesity drug Zimulti because of concerns it may increase suicidal thinking and depression. However, some experts predict that anti-obesity drugs will eventually work as reliably as anti-hypertensives and lipid regulators.
The study critically examines the market for anti-obesity drugs concentrating on types of anti-obesity treatments available as well as key industrial players in the sector. It forecasts to 2012 and identifies future leading therapeutic agents.
“Anti-Obesity Treatments 2007-2012 - A Blockbuster Target Market” is available from Report Buyer. For more information go to: http://www.reportbuyer.com/
Report Buyer product ID: VIS00060
